CpG-DNA exerts antibacterial effects by protecting immune cells and producing bacteria-reactive antibodies

Area of Science:

• Immunology
• Microbiology
• Pharmacology

Background:

• CpG-DNA activates immune cells for host defense against bacteria.
• The role of CpG-DNA in producing bacteria-reactive antibodies requires further investigation.

Purpose of the Study:

• To examine the biological function of CpG-DNA in the production of bacteria-reactive antibodies.
• To assess the therapeutic potential of CpG-DNA and bacteria-reactive monoclonal antibodies against antibiotic-resistant bacterial infections.

Main Methods:

• Mice were infected with methicillin-resistant S. aureus (MRSA) and treated with CpG-DNA.
• Immune cell populations, antibody production, and phagocytic activity were analyzed.
• Toll-like receptor 9 (TLR9) dependency was investigated.
• Bacteria-reactive monoclonal antibodies were tested for efficacy in vitro and in vivo.

Main Results:

• CpG-DNA administration increased survival and protected immune cells in mice infected with MRSA.
• CpG-DNA enhanced bacteria-reactive antibody production in peritoneal fluid and serum, dependent on TLR9.
• CpG-DNA stimulated B cells to produce bacteria-reactive antibodies, enhancing phagocytosis.
• A bacteria-reactive monoclonal antibody improved phagocytosis and protected mice against S. aureus infection.

Conclusions:

• CpG-DNA enhances antibacterial immunity by protecting immune cells and stimulating bacteria-reactive antibody production.
• Monoclonal antibodies show promise for treating antibiotic-resistant bacterial infections.